Pharmacokinetics of peptide-Fc fusion proteins

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 53-64

  Wu, Benjamin ^a   Sun, Yu Nien ^a  

^a AMGEN INC   (United States)

Author keywords

cancer; pharmacodynamics; pharmacokinetics; pharmacokinetics pharmacodynamics; simulations

Indexed keywords

ANGIOPOIETIN; ANTIMYOSTATIN PEPTIDE IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC PEPTIDE IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; B CELL ACTIVATING FACTOR; CHIMERIC PROTEIN; CNTO 528; CNTO 530; DIPEPTIDYL PEPTIDASE IV; DULAGLUTIDE; ERYTHROPOIETIN; FC RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLYCYLGLYCYLSERINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT PEPTIDE FUSION PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PEPTIBODY; PEPTIDE; RECOMBINANT PROTEIN; RITUXIMAB; ROMIPLOSTIM; TREBANANIB; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHRONIC IMMUNE THROMBOCYTOPENIA; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; ERYTHROPOIESIS; HUMAN; LIGAND BINDING; MASS SPECTROMETRY; MUSCLE ATROPHY; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; URINARY EXCRETION;

CANCER; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOKINETICS/PHARMACODYNAMICS; SIMULATIONS;

ANIMALS; DRUG DISCOVERY; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; PEPTIDES; RECEPTORS, FC;

EID: 84890520845     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23783     Document Type: Review

References (87)

1. Dimitrov DS,. 2012. Therapeutic proteins. Methods Mol Biol 899: 1-26.
2. [No author listed] 2013. United States Food and Drug Administration. CDER billable biologic products list. http://www.fda.gov/downloads/ForIndustry/ UserFees/PrescriptionDrugUserFee/UCM164641.pdf. Accessed May 6, 2013.
3. Brady K, Webster R,. 2012. Disposition of biologics. Adv Pharmacol 63: 257-277.
4. Kontos S, Hubbell JA,. 2012. Drug development: Longer-lived proteins. Chem Soc Rev 41 (7): 2686-2695.
5. Tang L, Persky AM, Hochhaus G, Meibohm B,. 2004. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93 (9): 2184-2204.
6. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X,. 2010. Biodistribution of [125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology. J Pharm Sci 99 (2): 1028-1045.
7. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW,. 2012. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 3 (4): 73-92.
8. Sato AK, Viswanathan M, Kent RB, Wood CR,. 2006. Therapeutic peptides: Technological advances driving peptides into development. Curr Opin Biotechnol 17 (6): 638-642.
9. Lobo ED, Hansen RJ, Balthasar JP,. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (11): 2645-2668.
10. Roopenian DC, Akilesh S,. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7 (9): 715-725.
11. Kim KJ, Malik AB,. 2003. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol 284 (2): L247-259.
12. Ladinsky MS, Huey-Tubman KE, Bjorkman PJ,. 2012. Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestine. Mol Biol Cell 23 (13): 2537-2545.
13. Brambell FW, Hemmings WA, Morris IG,. 1964. A theoretical model of gamma-globulin catabolism. Nature 203: 1352-1354.
14. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE,. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 89 (4): 573-578.
15. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES,. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15 (7): 637-640.
16. Frazer JK, Capra JD,. 1999. Fundamental immunology. Immunoglobulins: Structure and Function, 4th ed. Philadelphia, Pennsylvania: Lippincott-Raven, pp 37-74.
17. Lynch CM, Hart BW, Grewal IS,. 2009. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. mAbs 1 (1): 2-11.
18. Hall MP, Gegg C, Walker K, Spahr C, Ortiz R, Patel V, Yu S, Zhang L, Lu H, DeSilva B, Lee JW,. 2010. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: Strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 12 (4): 576-585.
19. Molineux G, Newland A,. 2010. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: From bench to bedside. Br J Haematol 150 (1): 9-20.
20. Shimamoto G, Gegg C, Boone T, Queva C,. 2012. Peptibodies: A flexible alternative format to antibodies. mAbs 4 (5): 586-591.
21. Kelley B,. 2009. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. mAbs 1 (5): 443-452.
22. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W,. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21 (6): 897-903.
23. Dintzis HM, Dintzis RZ, Vogelstein B,. 1976. Molecular determinants of immunogenicity: The immunon model of immune response. Proc Natl Acad Sci USA 73 (10): 3671-3675.
24. Sutherland S,. 2004. Peptibodies: The new cool technology. Drug Discov Today 9 (16): 683.
25. ® (romiplostim) prescribing information. http://pi.amgen.com/ united-states/nplate/nplate-pi-hcp-english.pdf Accessed April 12, 2013.
26. Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN,. 2011. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res 28 (8): 1931-1938.
27. Robson EJ, Ghatage P,. 2011. AMG 386: Profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 20 (2): 297-304.
28. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R,. 2004. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (5): 507-516.
29. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS,. 2009. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27 (21): 3557-3565.
30. Wu B, Johnson J, Soto M, Ponce M, Calamba D, Sun YN,. 2012. Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models. Pharm Res 29 (4): 1057-1065.
31. Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, Yohrling J, Frederick B, Marciniak S, Jiao Q, Jang H, Davis H, Burggraaf J,. 2008. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 48 (10): 1197-1207.
32. Perez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis HM,. 2009. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet 48 (9): 601-613.
33. Bugelski P, Nesspor T, Spinka-Doms T, Makropoulos D, Eirikis E, Fisher J, Volk A, Shamberger K, James I, Fisher P, Pool C, Jang H, Miller B, Huang C, Heavner G, Knight D, Ghrayeb J, Scallon B,. 2005. Pharmacokinetics and pharmacodynamics of CNTO 528, a novel erythropoietin receptor agonist in normal and anemic rats. Blood 106:abstract #4261.
34. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C,. 2008. CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 134 (1-2): 171-180.
35. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM,. 2009. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 113 (20): 4955-4962.
36. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N, Etgen G, Bumol T,. 2010. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26 (4): 287-296.
37. Soltani N, Kumar M, Glinka Y, Prud'homme GJ, Wang Q,. 2007. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 14 (12): 981-988.
38. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B,. 2011. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 13 (5): 434-438.
39. Mezo AR, McDonnell KA, Low SC, Song J, Reidy TJ, Lu Q, Amari JV, Hoehn T, Peters RT, Dumont J, Bitonti AJ,. 2012. Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: Semisynthesis, in vitro activity and pharmacokinetics in rats. Bioconjug Chem 23 (3): 518-526.
40. Lu SC, Atangan L, Won Kim K, Chen MM, Komorowski R, Chu C, Han J, Hu S, Gu W, Veniant M, Wang M,. 2012. An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice. J Lipid Res 53 (4): 643-652.
41. Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE,. 2011. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25 (5): 1653-1663.
42. European Medicines Agency, London, UK. 2009. Nplate European public assessment report, summary of product characteristics, pp 1-106. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000942/human-med-000938.jsp&mid=WC0b01ac058001d124. Accessed August 2, 2013.
43. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP, Wrighton NC, Barrett RW, Dower WJ,. 1997. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276 (5319): 1696-1699.
44. Broudy VC, Lin NL,. 2004. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25 (2): 52-60.
45. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcon BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD,. 2010. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9 (10): 2641-2651.
46. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH, Jr., Brown JV, III, Covens A, Nagarkar RV, Davy M, Leath CA, III, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB., III,. 2012. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30 (4): 362-371.
47. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P,. 2010. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16 (11): 3044-3056.
48. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B,. 2012. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118 (24): 6152-6161.
49. Eatock M, Tebbutt N, Bampton CL, Strickland A, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun Y-N, Zhong D, Bass MB, Adewoye AH, Bodoky G,. 2013. Phase 2 randomized, double-blind, placebo-controlled study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 24 (3): 710-718.
50. Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R, Tebbutt NC,. 2013. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 108 (3): 503-511.
51. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, Livnah O, Wrighton NC, Middleton SA, Loughney DA, Stura EA, Dower WJ, Mulcahy LS, Wilson IA, Jolliffe LK,. 1998. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry (Mosc) 37 (11): 3699-3710.
52. Kieffer TJ, McIntosh CH, Pederson RA,. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (8): 3585-3596.
53. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z,. 2012. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 29 (10): 1260-1267.
54. Geiger MJ, Skrivanek Z, Gaydos B, Chien J, Berry S, Berry D,. 2012. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): Trial design and baseline characteristics. J Diabetes Sci Technol 6 (6): 1319-1327.
55. Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, Richards AM,. 1997. Clearance receptors and endopeptidase: Equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 273 (5 Pt 2): H2372-H2379.
56. McPherron AC, Lawler AM, Lee SJ,. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (6628): 83-90.
57. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL,. 2004. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18 (1): 39-51.
58. Meibohm B, Zhou H,. 2012. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 52 (1 suppl): 54S-62S.
59. Meijer DFK, Ziegler K,. 1993. Mechanism for the hepatic clearance of oligopeptides and proteins. Implications for rate elimination, bioavailability, and cell-specific drug delivery to the liver. In Biological barriers to protein delivery;, Audus KL, Raub TJ, Eds. III ed. New York: Plenum Press, pp 339-408.
60. Deen WM,. 2004. What determines glomerular capillary permeability? J Clin Invest 114 (10): 1412-1414.
61. Tanner GA,. 2009. Kidney function. In Medical physiology: Principles for clinical medicine;, Rhoades RA, Bell DR, Eds. III ed., Baltimore, Maryland: Lippincott Williams & Wilkins, pp 391-418.
62. Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN,. 2012. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 69 (5): 1135-1144.
63. Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS,. 2008. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA 105 (3): 967-972.
64. Haymann JP, Levraud JP, Bouet S, Kappes V, Hagege J, Nguyen G, Xu Y, Rondeau E, Sraer JD,. 2000. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11 (4): 632-639.
65. Sarav M, Wang Y, Hack BK, Chang A, Jensen M, Bao L, Quigg RJ,. 2009. Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol 20 (9): 1941-1952.
66. Rabkin R, Ryan MP, Duckworth WC,. 1984. The renal metabolism of insulin. Diabetologia 27 (3): 351-357.
67. Kagan L, Turner MR, Balu-Iyer SV, Mager DE,. 2012. Subcutaneous absorption of monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 29 (2): 490-499.
68. Wang W, Wang EQ, Balthasar JP,. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84 (5): 548-558.
69. Mould DR, Sweeney KRD,. 2007. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10 (1): 84-96.
70. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzales M, Bakshi A, Padilla-Eagar J, Fielder PJ,. 2005. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33 (5): 623-629.
71. Mager DE,. 2006. Target-mediated drug disposition and dynamics. Biochem Pharmacol 72 (1): 1-10.
72. Mager DE, Jusko WJ,. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28 (6): 507-532.
73. Levy G,. 1994. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56 (3): 248-252.
74. Baillie TA, Rettie AE,. 2011. Role of biotransformation in drug-induced toxicity: Influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 26 (1): 15-29.
75. Kagan L, Mager DE,. 2013. Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos 41 (1): 248-255.
76. Agoram BM, Martin SW, van der Graaf PH,. 2007. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 12 (23-24): 1018-1024.
77. Yamazaki S,. 2013. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: A case study of anticancer drug, crizotinib. AAPS J 15 (2): 354-366.
78. Gibbs JP,. 2010. Prediction of exposure-response relationships to support first-in-human study design. AAPS J 12 (4): 750-758.
79. US FDA. 2003. Guidance for industry: Exposure-response relationships-Study design, data analysis, and regulatory applications. Rockville, Maryland: US Department of Health and Human Services Food and Drug Administration.
80. Luu KT, Kraynov E, Kuang B, Vicini P, Zhong WZ,. 2013. Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J 15 (2): 551-558.
81. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT,. 2010. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 12 (4): 729-740.
82. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S,. 2011. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118 (1): 28-36.
83. Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL,. 2007. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study. J Clin Pharmacol 47 (12): 1489-1497.
84. Wang B, Nichol JL, Sullivan JT,. 2004. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 (6): 628-638.
85. Hansen RJ, Balthasar JP,. 2003. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92 (6): 1206-1215.
86. Sharma V, McNeill JH,. 2009. To scale or not to scale: The principles of dose extrapolation. Br J Pharmacol 157: 907-921.
87. Chen T, Mager DE, Kagan L,. 2013. Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res 30 (3): 751-760.